Bempegaldesleukin

DB15140Investigational

Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib...

Mechanism: Pharmacologically active on Interleukin-2 receptor subunit beta and Interleukin-2 receptor
Curator reviewed
Code names: NKTR-214

Resolves to

Compound

UNIIBNO1JG5MZCCAS1939126-74-5

Targets

P14784IL2RB

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

21Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bempegaldesleukin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account